Cleveland Clinic, Cleveland, Ohio.
Icahn School of Medicine at Mount Sinai, New York, New York.
Heart Rhythm. 2018 Jul;15(7):1023-1030. doi: 10.1016/j.hrthm.2018.04.022.
Leadless cardiac pacemakers (LCPs) aim to mitigate lead- and pocket-related complications seen with transvenous pacemakers (TVPs).
The purpose of this study was to compare complications between the LCP cohort from the LEADLESS Pacemaker IDE Study (Leadless II) trial and a propensity score-matched real-world TVP cohort.
The multicenter LEADLESS II trial evaluated the safety and efficacy of the Nanostim LCP (Abbott, Abbott Park, IL) using structured follow-up, with serious adverse device effects independently adjudicated. TVP data were obtained from Truven Health MarketScan claims databases for patients implanted with single-chamber TVPs between April 1, 2010 and March 31, 2014 and more than 1 year of preimplant enrollment data. Comorbidities and complications were identified via International Classification of Diseases, Ninth Revision and Current Procedural Terminology codes. Short-term (≤1 months) and mid-term (>1-18 months) complications were compared between the LCP cohort and a propensity score-matched subset of the TVP cohort.
Among 718 patients with LCPs (mean age 75.6 ± 11.9 years; 62% men) and 1436 patients with TVPs (mean age 76.1 ± 12.3 years; 63% men), patients with LCPs experienced fewer complications (hazard ratio 0.44; 95% confidence interval 0.32-0.60; P < .001), including short-term (5.8% vs 9.4%; P = .01) and mid-term (0.56% vs 4.9%; P < .001) events. In the short-term time frame, patients with LCPs had more pericardial effusions (1.53% vs 0.35%; P = .005); similar rates of vascular events (1.11% vs 0.42%; P = .085), dislodgments (0.97% vs 1.39%; P = .54), and generator complications (0.70% vs 0.28%; P = .17); and no thoracic trauma compared to patients with TVPs (rate of thoracic trauma 3.27%). In short- and mid-term time frames, TVP events absent from the LCP group included lead-related, pocket-related, and infectious complications.
Patients with LCPs experienced fewer overall short- and mid-term complications, including infectious and lead- and pocket-related events, but more pericardial effusions, which were uncommon but serious.
无导线心脏起搏器(LCP)旨在减轻经静脉起搏器(TVP)中出现的导线和囊袋相关并发症。
本研究旨在比较 LEADLESS 起搏器 IDE 研究(Leadless II)试验中 LCP 队列与倾向评分匹配的真实世界 TVP 队列之间的并发症。
多中心的 Leadless II 试验使用结构化随访评估了 Nanostim LCP(雅培,雅培公园,IL)的安全性和疗效,严重不良器械效应由独立裁决。TVP 数据来自 Truven Health MarketScan 索赔数据库,用于 2010 年 4 月 1 日至 2014 年 3 月 31 日期间植入单腔 TVP 的患者和超过 1 年的植入前登记数据。通过国际疾病分类,第九版和当前程序术语代码识别合并症和并发症。比较 LCP 队列和 TVP 队列中倾向评分匹配子集之间的短期(≤1 个月)和中期(>1-18 个月)并发症。
在 718 例 LCP 患者(平均年龄 75.6 ± 11.9 岁;62%为男性)和 1436 例 TVP 患者(平均年龄 76.1 ± 12.3 岁;63%为男性)中,LCP 组发生的并发症较少(风险比 0.44;95%置信区间 0.32-0.60;P <.001),包括短期(5.8%比 9.4%;P =.01)和中期(0.56%比 4.9%;P <.001)事件。在短期时间范围内,LCP 组患者发生更多的心包积液(1.53%比 0.35%;P =.005);血管事件(1.11%比 0.42%;P =.085)、脱位(0.97%比 1.39%;P =.54)和发生器并发症(0.70%比 0.28%;P =.17)的发生率相似;与 TVP 患者相比,LCP 组无胸部创伤(胸部创伤发生率 3.27%)。在短期和中期时间范围内,LCP 组中没有出现与导联相关、囊袋相关和感染性并发症的 TVP 事件。
LCP 组患者经历的总体短期和中期并发症较少,包括感染和导联及囊袋相关事件,但心包积液较多,心包积液虽不常见但很严重。